These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

730 related articles for article (PubMed ID: 27774703)

  • 21. β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial.
    Bangalore S; Bhatt DL; Steg PG; Weber MA; Boden WE; Hamm CW; Montalescot G; Hsu A; Fox KA; Lincoff AM
    Circ Cardiovasc Qual Outcomes; 2014 Nov; 7(6):872-81. PubMed ID: 25271049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction.
    Lund LH; Benson L; Dahlström U; Edner M; Friberg L
    JAMA; 2014 Nov; 312(19):2008-18. PubMed ID: 25399276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers.
    Brooks TW; Creekmore FM; Young DC; Asche CV; Oberg B; Samuelson WM
    Pharmacotherapy; 2007 May; 27(5):684-90. PubMed ID: 17461703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential Effect of β-Blockers According to Heart Rate in Acute Myocardial Infarction Without Heart Failure or Left Ventricular Systolic Dysfunction: A Cohort Study.
    Park JJ; Kim SH; Kang SH; Yoon CH; Suh JW; Cho YS; Youn TJ; Chae IH; Choi DJ
    Mayo Clin Proc; 2019 Dec; 94(12):2476-2487. PubMed ID: 31806101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
    Kenchaiah S; Davis BR; Braunwald E; Rouleau JL; Dagenais GR; Sussex B; Steingart RM; Brown EJ; Lamas GA; Gordon D; Bernstein V; Pfeffer MA;
    Am Heart J; 2004 Aug; 148(2):356-64. PubMed ID: 15309009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. β-Blocker Use and Clinical Outcomes in Patients With COPD Following Acute Myocardial Infarction.
    LaFon DC; Helgeson ES; Lindberg S; Voelker H; Bhatt SP; Casaburi R; Cassady SJ; Connett J; Criner GJ; Hatipoglu U; Kaminsky DA; Kunisaki KM; Lazarus SC; McEvoy CE; Reed RM; Sciurba FC; Stringer W; Dransfield MT
    JAMA Netw Open; 2024 May; 7(5):e247535. PubMed ID: 38771577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. β-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis.
    Zhou H; Sim JJ; Shi J; Shaw SF; Lee MS; Neyer JR; Kovesdy CP; Kalantar-Zadeh K; Jacobsen SJ
    Am J Kidney Dis; 2021 May; 77(5):704-712. PubMed ID: 33010357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease.
    Lipworth B; Skinner D; Devereux G; Thomas V; Ling Zhi Jie J; Martin J; Carter V; Price DB
    Heart; 2016 Dec; 102(23):1909-1914. PubMed ID: 27380949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decreased Mortality With Beta-Blockers in Patients With Heart Failure and Coexisting Atrial Fibrillation: An AF-CHF Substudy.
    Cadrin-Tourigny J; Shohoudi A; Roy D; Talajic M; Tadros R; Mondésert B; Dyrda K; Rivard L; Andrade JG; Macle L; Guerra PG; Thibault B; Dubuc M; Khairy P
    JACC Heart Fail; 2017 Feb; 5(2):99-106. PubMed ID: 28089316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study.
    Puymirat E; Riant E; Aissaoui N; Soria A; Ducrocq G; Coste P; Cottin Y; Aupetit JF; Bonnefoy E; Blanchard D; Cattan S; Steg G; Schiele F; Ferrières J; Juillière Y; Simon T; Danchin N
    BMJ; 2016 Sep; 354():i4801. PubMed ID: 27650822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience.
    Stephenson K; Skali H; McMurray JJ; Velazquez EJ; Aylward PG; Kober L; Van de Werf F; White HD; Pieper KS; Califf RM; Solomon SD; Pfeffer MA
    Heart Rhythm; 2007 Mar; 4(3):308-13. PubMed ID: 17341394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
    Shavadia JS; Zheng Y; Green JB; Armstrong PW; Westerhout CM; McGuire DK; Cornel JH; Holman RR; Peterson ED
    Am Heart J; 2019 Dec; 218():92-99. PubMed ID: 31715435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beta-blocker use and acute exacerbations of COPD following myocardial infarction: a Danish nationwide cohort study.
    Rasmussen DB; Bodtger U; Lamberts M; Torp-Pedersen C; Gislason G; Lange P; Jensen MT
    Thorax; 2020 Nov; 75(11):928-933. PubMed ID: 32820080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial.
    Kristensen AMD; Bovin A; Zwisler AD; Cerquira C; Torp-Pedersen C; Bøtker HE; Gustafsson I; Veien KT; Thomsen KK; Olsen MH; Larsen ML; Nielsen OW; Hildebrandt P; Foghmar S; Jensen SE; Lange T; Sehested T; Jernberg T; Atar D; Ibanez B; Prescott E
    Trials; 2020 May; 21(1):415. PubMed ID: 32446298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beta-blocker use in ST-segment elevation myocardial infarction in the reperfusion era (GRACE).
    Park KL; Goldberg RJ; Anderson FA; López-Sendón J; Montalescot G; Brieger D; Eagle KA; Wyman A; Gore JM;
    Am J Med; 2014 Jun; 127(6):503-11. PubMed ID: 24561113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study.
    Sorbets E; Steg PG; Young R; Danchin N; Greenlaw N; Ford I; Tendera M; Ferrari R; Merkely B; Parkhomenko A; Reid C; Tardif JC; Fox KM;
    Eur Heart J; 2019 May; 40(18):1399-1407. PubMed ID: 30590529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of cardioselective β-blockers and overall death and cardiovascular outcomes in patients with COPD: a population-based cohort study.
    Dong YH; Chang CH; Wu LC; Lai MS
    Eur J Clin Pharmacol; 2016 Oct; 72(10):1265-1273. PubMed ID: 27444174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
    J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
    Aguilar D; Solomon SD; Køber L; Rouleau JL; Skali H; McMurray JJ; Francis GS; Henis M; O'Connor CM; Diaz R; Belenkov YN; Varshavsky S; Leimberger JD; Velazquez EJ; Califf RM; Pfeffer MA
    Circulation; 2004 Sep; 110(12):1572-8. PubMed ID: 15364810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term β-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study.
    Kim J; Kang D; Park H; Kang M; Park TK; Lee JM; Yang JH; Song YB; Choi JH; Choi SH; Gwon HC; Guallar E; Cho J; Hahn JY
    Eur Heart J; 2020 Oct; 41(37):3521-3529. PubMed ID: 32542362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.